A new era of antiretroviral drug toxicity

Antiviral Therapy

Volumn 14, Issue 2, 2009, Pages 165-179

  Calmy, Alexandra ^a   Hirschel, Bernard ^a   Cooper, David A ^b,c   Carr, Andrew ^c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ERGOT ALKALOID; ETRAVIRINE; HYPNOTIC AGENT; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; NEW DRUG; NUCLEOSIDE DERIVATIVE; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ADIPOSE TISSUE; ANEMIA; ASTHENIA; ATRIOVENTRICULAR BLOCK; BONE TISSUE; BRAIN HEMORRHAGE; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; ERYTHEMA MULTIFORME; FATTY LIVER; FEVER; GLOMERULUS FILTRATION RATE; HEADACHE; HEALTH CARE ACCESS; HEALTH CARE PLANNING; HEART; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLACTATEMIA; HYPERSENSITIVITY REACTION; HYPERTRIGLYCERIDEMIA; INGROWN NAIL; INSOMNIA; KIDNEY PARENCHYMA; KIDNEY TUBULE DISORDER; LACTIC ACIDOSIS; LIPOATROPHY; LIVER; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOMA; MUSCLE WEAKNESS; NAIL PIGMENTATION; NAUSEA; NEPHROLITHIASIS; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; OSTEOPENIA; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SCALE UP; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TISSUE SPECIFICITY; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIVID DREAM; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG SCREENING; GENETIC VARIABILITY; GENETICS; HIV ASSOCIATED LIPODYSTROPHY; HUMAN IMMUNODEFICIENCY VIRUS; KIDNEY DISEASE; LIVER DISEASE; METABOLIC BONE DISEASE;

ANTI-RETROVIRAL AGENTS; BONE DISEASES, METABOLIC; CARDIOVASCULAR DISEASES; DRUG EVALUATION; GENETIC VARIATION; HEALTH RESOURCES; HIV; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; KIDNEY DISEASES; LIVER DISEASES;

EID: 67149140490     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (115)

1. Flexner C. HIV drug development: the next 25 years. Nat Rev Drug Discov 2007; 6:959-966.
2. + count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
3. Cote HCF, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346:811-820.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US Department of Health and Human Services. 29 January 2008. (Updated 29 January 2008. Accessed 30 June 2008.) Available from http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf
5. EACS. European AIDS Clinical Society guidelines. (Updated June 2008. Accessed 24 September 2008.) Available from www.eacs.eu/guide/ index.htmine
6. Cossarizza A, Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 2004; 18:137-151.
7. Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000; 31:162-166.
8. Bonnet F, Bonarek M, Morlat P, et al. Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: a case-control study. Clin Infect Dis 2003; 36:1324-1328.
9. Bonnet F, Bonarek M, Abrij A, Beylot J, Morlat P. Metabolic acidosis in HIV-infected patients. Clin Infect Dis 2002; 34:1289-1290.
10. Wester CW, Okezie OA, Thomas AM, et al. Higher-than-expected rates of lactic acidosis among HAART-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr 2007; 46:318-322.
11. Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy. Clin Infect Dis 2001; 33:1931-1937.
12. Hocqueloux L, Alberti C, Feugas JP, et al. Prevalence, risk factors and outcome of hyperlactatemia in HIV-infected patients. HIV Med 2003; 4:18-23.
13. Marceau G, Sapin V, Jacomet C, et al. Frequency, risk factors, and outcome of hyperlactatemia in HIV-positive persons: implications for the management of treated patients. Clin Chem 2003; 49:1154-1162.
14. Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D, Gazzard BG. Hyperlactatemia and lactic acidosis during antiretroviral therapy: relevance, reproductibility, and possible risk factor. AIDS 2002; 16:1341-1349.
15. Vrouenraets SM, Treskes M, Regez RM, et al. Hyperlactatemia in HIV-infected patients: the role of NRTI-treatment. Antivir Ther 2002; 7:239-244.
16. Bonnet F, Balestre E, Bernardin E, et al. Risk factors for hyperlactatemia in HIV-infected patients, Aquitaine Cohort, 1999-2003. Antivir Chem Chemother 2005; 16:63-67.
17. Rivas P, Polo J, de Górgolas M, Fernández-Guerrero ML. Drug points: fatal lactic acidosis associated with tenofovir. BMJ 2003; 327:711.
18. Servoss JC, Kitch DW, Andersen JW, Reisler RB, Chung RT, Robbins K. Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999). J Acquir Immune Defic Syndr 2006; 43:320-323.
19. Cattelan AM, Erne E, Slatino A, et al. Severe hepatic failure related to nevirapine treatment. Clin Infect Dis 1999; 29:455-456.
20. Wit FW, Kesselring AM, Gras L, et al. Discontinuation of nevirapine due to hypersensitivity reactions in patients with prior treatment-experience compared to treatment-naïve patients: the ATHENA cohort study. Clin Infect Dis 2008; 46:933-940.
21. US Food and Drug Administration. Food and Drug Administration darunavir black box warning. (Updated March 2008. Accessed 15 May 2008.) Available from http://www.fda.gov/cder/drug/infopage/darunavir/default.htm
22. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568-579.
23. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23:1603-1614.
24. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359:727-732.
25. Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 2005; 19:97-99.
26. Haas DW, Bartlett JA, Andersen JW, et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group Collaboration. Clin Infect Dis 2006; 43:783-786.
27. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group Study. AIDS 2004; 18:2391-2400.
28. Rotger M, Telenti A. Optimizing efavirenz treatment: CYP2D6 genotyping or therapeutic drug monitoring. Eur J Clin Pharmacol 2008; 64:335-336.
29. Gatanaga H, Hayashida T, Tsuchiya K, et al. Successful efavirenz dose reduction in HIV-1 infected individuals with cytochrome P450 2B6*6 and *26. Clin Infect Dis 2007; 45:1230-1237.
30. Mayosi BM. Contemporary trends in the epidemiology and management of cardiomyopathy and pericarditis in sub-Saharan Africa. Heart 2007; 93:1176-1183.
31. Grinspoon SK, Grunfeld C, Kotler DP, Currier JS, Lundgren JD, Dubé MP. State of the science conference: initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation 2008; 118:198-210.
32. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
33. The DAD study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.
34. Dressman J, Kincer J, Matveev SV, et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest 2003; 111:389-397.
35. D:A:D Study group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417-1426.
36. SMART/INSIGHT and the D:A:D Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17-F24.
37. + count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
38. Carr A, Ory D. Does HIV cause cardiovascular disease? PLoS Med 2006; 3:e496.
39. Mujawar Z, Rose H, Morrow MP, et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 2006; 4:e365.
40. Van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001; 15:2407-2414.
41. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008. 5:e203.
42. Calmy A, Nguyen A, Montecucco F, et al. HIV activates markers of cardiovascular risk in a randomized treatment interruption trial. AIDS 2009. In press.
43. Law MG, Friis-Moller N, El-Sadr WM, et al. The use of Framingham equation to predict myocardial infacrtions in HIV-infected patients: comparison ith obseverd events in the D:A:D study. HIV Med 2006; 7:218-230.
44. De Jesus E, Walmsley S, Cohen C, et al. Fasted lipid changes after administration of maraviroc or efavirenz in combination with zidovudine and lamivudine for 48 weeks to treatment naive HIV-infected patients. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA.
45. Moyle G, Fisher M. A randomized comparison of continued zidovudine plus lamivudine BID (AZT/3TC) vs switching to tenofovir DF plus emtricitabine (FTC/TDF) each plus efavirenz (EFV) in stable HIV infected persons: 48 week study - results of a planned 24 week analysis. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 22-25 July 2007, Sydney, Australia.
46. Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20:2043-2050.
47. Martínez E, Arnaiz J, De Lazzari E, Cruceta A, Gatell J. 3-year final results of a simplification trial with nevirapine, efavirenz, or abacavir as substitutes of protease inhibitors in patients with HIV infection (the NEFA study). 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February 2006, Denver, CO, USA.
48. Mallolas J, Podzamczer D, Domingo P, et al. Efficacy and safety of switching from lopinavir/r (LPV/r) to atazanavir/r (ATV/r) in patients with virologic suppression receiving a LPV/r containing HAART: the ATAZIP study. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 22-25 July 2007, Sydney, Australia.
49. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN study (AI424-097) 48-week results. Clin Infect Dis 2007; 44:1484-1492.
50. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58.
51. Carr A, Samaras K, Thorisdottir A, Kaufmann G, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus. Lancet 1999; 353:2093-2099.
52. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13:1659-1667.
53. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001; 50:1378-1388.
54. Calmy A, Carey D, Mallon P, et al. Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy. HIV Med 2008; 9:101-110.
55. Study of Fat Redistibution and Metabolic Change in HIV Infection (FRAM). Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40:121-131.
56. Boyd MA, Carr A, Ruxrungtham K, et al. Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz. J Infect Dis 2006; 194:642-650.
57. Nguyen A, Calmy A, Bernasconi E, et al. Lipodystrophy is not what it used to be: data from the Swiss HIV cohort study. HIV Med 2008; 9:142-150.
58. Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007; 44:139-147.
59. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination. A 3-year randomized trial. JAMA 2004; 292:191-201.
60. Pérez-Molina JA, Domingo P, Martínez E, Moreno S. The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy. J Antimicrob Chemother 2008; 62:234-245.
61. Dubé MP, Komarow L, Mulligan K, et al. Long-term body fat outcomes in antiretroviral-naive participants randomized to elfinavir or efavirenz or both plus dual nucleosides. Dual X ray absorbsiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr 2007; 45:508-514.
62. Jemsek JG, Arathoon E, Arlotti M, et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis 2006; 42:273-280.
63. Haubrich RH, Riddler SA, DiRienzo G, et al. Metabolic outcomes of ACTG5142: a prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA.
64. Wohl D, Lancaster T, DeJesus E et al. Determination of body composition changes by total body dual-energy x-ray absorptiometry after 48 weeks of treatment with once-daily fosamprenavir (FPV) boosted with two different doses of ritonavir(r) plus abacavir (ABC)/lamivudine (3TC): COL100758. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 22-25 July 2007, Sydney, Australia.
65. Carr A, Zajdenverg R, Workman C, et al. Effects of tipranavir/ ritonavir (500/200 or 500/100 mg BID) in comparison with lopinavir/ ritonavir (400/100 mg BID) on changes in body composition and metabolic parameters in ARV-naive patients over 48 weeks. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. 22-25 July 2007, Sydney, Australia.
66. Mangili A, Jacobson DL, Gerrioir J, Polak JF, Gorback SL, Wanke CA. Metabolic syndrome and subclinical atherosclerosis in patients infected with HIV. Clin Infect Dis 2007; 44:1368-1374.
67. Wand H, Calmy A, Carey D, et al. Metabolic syndrome, cardiovascular disase and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007; 21:2445-2453.
68. Martin A, Smith D, Carr A, et al. Changes in lipodystrophy 2 years after switching from thymidine nucleoside analogues to abacavir. AIDS 2004; 18:1029-1036.
69. John M, McKinnon EJ, James IR, et al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr 2003; 33:29-33.
70. Carey DL, Baker D, Rogers GD, et al. A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy. J Acquir Immune Defic Syndr 2007; 46:581-589.
71. Arioglu E, Duncan-Morin J, Sebring N, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000; 133:263-274.
72. Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for HIV-1 lipoatrophy: a randomised, double-blind, placebo-controlled trial. Lancet 2004; 363:429-438.
73. Slama L, Lanoy E, Valentin M-A, et al. Effect of pioglitazone on HIV-1 related lipoatrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antivir Ther 2008; 13:67-76.
74. Walker UA, Langmann P, Miehle N, Zilly M, Klinker H, Petchner F. Beneficial effects of oral uridine in mitochondrial toxicity. AIDS 2004; 18:1085-1086.
75. Sutinen J, Walker UA, Sevastianova K, Hakkinen AM, Ristola M, Yki-Jarvinen H. Uridine supplementation increases subcutaneous fat in patients with HAART - associated lipodystrophy (HAL) - a randomized, placebo-controlled trial. Antivir Ther 2007; 12:97-105.
76. Mallon PWG, Miller J, Kovacic JC, et al. Effects of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men: a randomised, placebo-controlled study. AIDS 2006; 20:1003-1010.
77. Macallan DC, Baldwin C, Mandalia S, et al. Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone. HIV Clin Trials 2008; 9:254-268.
78. Mulligan K, Yang Y, Wininger DA, et al. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS 2007; 21:47-57.
79. Martinez E, Domingo P, Ribera E, et al. Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors. Antivir Ther 2003; 8:403-410.
80. Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS 2008; 22:1719-1728.
81. Malita FM, Karelis AD, Toma E, Rabasa-Lhoret R. Effects of different types of exercise on body composition and fat distribution in HIV-infected patients: a brief review. Can J Appl Physiol 2005; 30:233-245.
82. Morse CG, Mican JM, Jones EC, et al. The incidence and natural history of osteonecrosis in HIV-infected adults. Clin Infect Dis 2007; 44:739-748.
83. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20:2165-2174.
84. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003; 36:482-490.
85. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among HIV-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008; 93:3499-3504.
86. McComsey GA, Kendall M, Tebas P, et al. Alendronate with calcium and vitamin D supplementation is superior to calcium and vitamin D alone in the management of decreased bone mineral density in HIV-infected patients: results of ACTG 5163. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA.
87. World Health Organization. WHO fracture risk assessment tool. (Updated 2008. Accessed 27 June 2008.) Available from http://www.shef.ac.uk/FRAX/ reference.htm
88. Fine DM, Pezzarola MA, Lucas GM, Atta MG. Renal disease in patients with HIV infection: epidemiology, pathogenesis and management. Drugs 2008; 68:963-980.
89. Boyd MA, Siangphoe U, Ruxrungtham K, et al. The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity. J Antimicrob Chemother 2006; 57:1161-1167.
90. Arribas JR, Pozniak AL, Gallent J, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine plus lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008; 47:74-78.
91. Gallant JE, Winston JA, DeJesus E, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS 2008; 22:2155-2163.
92. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007; 21:1273-1281.
93. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40:1194-1198.
94. Fux CA, Christen A, Zgaggen S, Mohaupt MG, Furrer H. Effect of tenofovir on renal glomerular and tubular function. AIDS 2007; 21:1483-1485.
95. Gupta SK, Eustache JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40:1559-1585.
96. World Health Organization. Towards Universal Access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2 June 2008. (Accessed 23 March 2009.) Available from http://www.who.int/hiv/ mediacentre/2008progressreport/en/index.html
97. Van Griensven J, De Naeyer L, Mushi T, et al. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hyg 2007; 101:793-798.
98. Pujari SN, Dravid A, Naik E, et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr 2005; 39:199-202.
99. Boulle A, Orrel C, Kaplan R, et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther 2007; 12:753-760.
100. Hill A, Ruxrungtham K, Hanvanich M, et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 2007; 8:679-688.
101. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. (Updated 7 August 2006. Accessed June 2008.) Available from http://www.who.int/hiv/pub/guidelines/en/
102. Reid W, Stöhr S, Walker F, et al. Glomerular dysfunction and associated risk factors following initiation of ART in adults with HIV infection in Africa. World AIDS Conference. 13-18 August 2008, Toronto, ON, Canada.
103. Subbaraman R, Chaguturu SK, Mayer KH, Flanigan TP, Kumarasamy N. Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis 2007; 45:1093-1101.
104. Kumarasamy N, Vallabhaneni S, Cecelia AJ, et al. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. J Acquir Immune Defic Syndr 2006; 41:53-58.
105. Phanuphak N, Apornpong T, Teeratakulpisarn S, et al. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women. HIV Med 2007; 8:357-366.
106. Ssali F, Stöhr W, Munderi P, et al. Incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV Infection within the DART Trial. Antivir Ther 2006; 11:741-749.
107. Huffam SE, Srasuebkul P, Zhou J, et al. Prior antiretroviral therapy experience protects against zidovudine-related anaemia. HIV Med 2007; 8:465-471.
108. Bolhaar MG, Karstaedt AS. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis 2007; 45:254-260.
109. Currier JS. Sex differences in antiretroviral therapy toxicity: lactic Acidosis, stavudine, and women. Clin Infect Dis 2007; 45:261-262.
110. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
111. Havlir DV. HIV integrase inhibitors - out of the pipeline and into the clinic. N Engl J Med 2008; 359:416-418.
112. Nichols WG, Steel HM, Bonny T, et al. Hepatotoxicity observed in clinical trails of aplaviroc (GW873140). Antimicrob Agents Chemother 2008; 52:858-865.
113. Mañes S, Mira E, Colomer R, et al. CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med 2003; 198:1381-1389.
114. Zingman B, Suleiman J, DeJesus E, et al. Vicriviroc, a next generation CCR5 antagonist, exhibits potent, sustained suppression of viral replication in treatment-experienced adults: VICTOR-E1 48-week results. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA.
115. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-1441.